A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma is a phase 3 interventional study registered as NCT06007690 by Aura Biosciences, with 108 participants enrolled, started 2023-12-06 and due to reach its primary completion in 2027-11-15. Interventions recorded: Bel-sar, Suprachoroidal Microinjector, Infrared Laser, Sham Infrared Laser and Sham Microinjector.